| Original language | English |
|---|---|
| Pages (from-to) | 163-166 |
| Number of pages | 4 |
| Journal | Journal of Attention Disorders |
| Volume | 22 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Jan 2018 |
Funding
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: In unrelated disclosures, Dr. Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, and YoungLiving (as well as NIH and Autism Speaks) and has consulted with or been on advisory boards for Arbor, Gowlings, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, and Tris Pharma and received travel support from Noven.
Keywords
- ADHD
- altitude
- circadian
- DRD4
- prevalence
- solar intensity